The effects of novel 7-MEOTA-donepezil like hybrids and N-alkylated tacrine analogues in the treatment of quinuclidinyl benzilate-induced behavioural deficits in rats performing the multiple T-maze test

Biomedical Papers

Volumn 159, Issue 4, 2015, Pages 547-553

  Misik, Jan ^a   Korabecny, Jan ^a   Nepovimova, Eugenie ^a   Cabelova, Pavla ^a   Kassa, Jiri ^a  

^a UNIVERSITY OF DEFENCE   (Czech Republic)

Author keywords

Acetylcholine; Acetylcholinesterase; Alzheimer disease; Donepezil; Spatial orientation; Tacrine

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; INDAN DERIVATIVE; MUSCARINIC RECEPTOR BLOCKING AGENT; NOOTROPIC AGENT; PIPERIDINE DERIVATIVE; QUINUCLIDINYL BENZILATE; TACRINE;

ANALOGS AND DERIVATIVES; ANIMAL; ANIMAL BEHAVIOR; DOSE RESPONSE; DRUG EFFECTS; MALE; MAZE TEST; WISTAR RAT;

ANIMALS; BEHAVIOR, ANIMAL; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; INDANS; MALE; MAZE LEARNING; MUSCARINIC ANTAGONISTS; NOOTROPIC AGENTS; PIPERIDINES; QUINUCLIDINYL BENZILATE; RATS, WISTAR; TACRINE;

EID: 84949679442     PISSN: 12138118     EISSN: 18047521     Source Type: Journal    
DOI: 10.5507/bp.2015.006     Document Type: Article

References (51)

1. Povova J, Ambroz P, Bar M, Pavukova V, Sery O, Tomaskova H, Janout V. Epidemiological of and risk factors for Alzheimer's disease. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2012;156(2):108-14.
2. Zemek F, Drtinova L, Nepovimova E, Sepsova V, Korabecny J, Klimes J, KucaK. Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine. Expert Opin Drug Saf 2014;13(6):759-74.
3. Contestabile A. The history of the cholinergic hypothesis. Behav Brain Res 2011;221(2):334-40.
4. Ghezzi L, Scarpini E, Galimberti D. Disease-modifying drugs in Alzheimer's disease. Drug Des Devel Ther 2013;7:1471-8.
5. Singh M, Kaur M, Kukreja H, Chugh R, Silakari O, Singh D. Acetylcholinesterase inhibitors as Alzheimer therapy: from nerve toxins to neuroprotection. Eur J Med Chem 2013;70:165-88.
6. Bejar C, Wang RH, Weinstock M. Effect of rivastigmine on scopolamine-induced memory impairment in rats. Eur J Pharmacol 1999;383:231-40.
7. Cheng DH, Tang XC. Comparative studies of huperzine A, E2020, and tacrine on behavior and cholinesterase activities. Pharmacol Biochem Behav 1998;60:377-86.
8. Poorheidari G, Stanhope KJ, Pratt JA. Effects of the potassium channel blockers, apamin and 4-aminopyridine, on scopolamine-induced deficits in the delayed matching to position task in rats: a comparison with the cholinesterase inhibitor E2020. Psychopharmacology 1998;135:42-255.
9. Korabecny J, Hruba E, Soukup O, Zemek F, Musilek K, Nepovimova E, Spilovska K, Opletalova V, Kuca K. Intended pharmacotherapeutical approaches of Alzheimer's disease therapy. Ceska Slov Farm 2012;61(1-2):4-10.
10. Giacobini E. Cholinesterase inhibitors stabilize Alzheimer disease. Neurochem Res 2000;25:1185-90.
11. Racchi M, Mazzucchelli M, Porrello E, Lanni,C, Govoni S. Acetylcholinesterase inhibitors: novel activities of old molecules. Pharmacol Res 2004;50:441-51.
12. Pohanka M. Cholinesterases, a target of pharmacology and toxicology. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2011;155(3):219-29.
13. Pohanka M. Acetylcholinesterase inhibitors: a patent review (2008 - present). Expert Opin Ther Pat 2012;22:871-86.
14. Bolognesi ML, Minarini A, Rosini M, Tumiatti V, Melchiorre C. From dual binding site acetylcholinesterase inhibitors to multi-target-directed ligands (MTDLs): a step forward in the treatment of Alzheimer's disease. Mini Rev Med Chem 2008;8(10):960-7.
15. Ambure P, Kar S, Roy K. Pharmacophore mapping-based virtual screening followed by molecular docking studies in search of potential acetylcholinesterase inhibitors as anti-Alzheimer's agents. Biosystems 2014;116:10-20.
16. Chen Y, Sun JF, Peng SX, Liao H, Zhang YH, Lehmann J. Tacrine- Flurbiprofen Hybrids as Multifunctional Drug Candidates for the Treatment of Alzheimer's Disease. Arch Pharm (Weinheim) 2013;346:865-71.
17. Minarini A, Milelli A, Simoni E, Rosini M, Bolognesi ML, Marchetti C, TumiattiV. Multifunctional tacrine derivatives in Alzheimer's disease. Curr Top Med Chem 2013;13(15):1771-86.
18. Romero A, Cacabelos R, Oset-Gasque MJ, Samadi A, Marco- Contelles J. Novel tacrine-related drugs as potential candidates for the treatment of Alzheimer's disease. Bioorg Med Chem Lett 2013;23(7):1916-22.
19. Spilovska K, Korabecny J, Kral J, Horova A, Musilek K, Soukup O, Drtinova L, Gazova Z, Siposova K, Kuca K. 7-Methoxytacrine-adamantylamine heterodimers as cholinesterase inhibitors in Alzheimer's disease treatment-synthesis, biological evaluation and molecular modelling studies. Molecules 201;18(2):2397-418.
20. Li SY, Jiang N, Xie SS, Wang KD, Wang XB, Kong LY. Design, synthesis and evaluation of novel tacrine-rhein hybrids as multifunctional agents for the treatment of Alzheimer's disease. Org Biomol Chem 2014;12(5):801-14.
21. Wei AC, Ali MA, Yoon YK, Ismail R, Choon TS, Khaw KY, Murugaiyah V, Lakshmipathi VS. Synthesis of Highly Functionalised Dispiropyrrolidine Derivatives as Novel Acetylcholinesterase Inhibitors. Lett Drug Des Discov 2014;11:156-61.
22. Mehta M, Adem A, Sabbagh M. New acetylcholinesterase inhibitors for Alzheimer's disease. Int J Alzheimers Dis 2012. [Epub ahead of print] doi:10.1155/2012/728983
23. Korabecny J, Musilek K, Holas O, Binder J, Zemek F, Marek J, Pohanka M, Opletalova V, Dohnal V, Kuca K. Synthesis and in vitro evalua- tion of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease. Bioorg Med Chem Lett 2010;20:6093-5.
24. Korabecny J, Dolezal R, Cabelova P, Horova A, Hruba E, Ricny J, Sedlacek L, Nepovimova E, Spilovska K, Andrs M, Musilek K, Opletalova V, Sepsova V, Ripova D, Kuca K. 7-MEOTA–donepezil like compounds as cholinesterase inhibitors: Synthesis, pharmacological evaluation, molecular modeling and QSAR studies. Eur J Med Chem 2014;82:426-38.
25. Korabecny J, Musilek K, Holas O, Nepovimova E, Jun D, Zemek F, Opletalova V, Patocka J, Dohnal V, Nachon F, Hroudova J, Fisar Z, Kuca K. Synthesis and in vitro evaluation of N-(Bromobut-3-en-2-yl)-7-methoxy-1,2,3,4-tetrahydroacridin-9-amine as a cholinesterase inhibitor with regard to Alzheimer's disease treatment. Molecules 2010;15(12):8804-12.
26. Korabecny J, Musilek K, Zemek F, Horova A, Holas O, Nepovimova E, Opletalova V, Hroudova J, Fisar Z, Jung YS, KucaK. Synthesis and in vitro evaluation of 7-methoxy-N-(pent-4-enyl)-1,2,3,4-tetrahy-droacridin-9-amine-new tacrine derivate with cholinergic properties. Bioorg Med Chem Lett 2011;21(21):6563-6.
27. Misik J, Vanek J, Musilek K, Kassa J. Cholinergic antagonist 3-quinuclidinyl benzilate - Impact on learning and memory in Wistar rats. Behav Brain Res 2014;266:193-200.
28. Anand P, Singh B. A review on cholinesterase inhibitors for Alzheimer's disease. Arch Pharm Res 2013;36(4):375-99.
29. Kassa J, Korabecny J, Sepsova V, Tumova M. The Evaluation of Prophylactic Efficacy of Newly Developed Reversible Inhibitors of Acetylcholinesterase in Soman-Poisoned Mice - A Comparison with Commonly Used Pyridostigmine. Basic Clin Pharmacol Toxicol 2014;115(6):571-6.
30. Ellman GL, Courtney DK, Andres VJr, Featherstone RM. A new and rapid determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88-93.
31. Kunesova G, Hlavacek J, Patocka J, Evangelou A, Zikos C, Benaki D, Paravatou-Petsotas M, Pelecanou M, Livaniou E, Slaninova J. The multiple T-maze in vivo testing of the neuroprotective effect of humanin analogues. Peptides 2008;29:1982-7.
32. De-Mello N, Carobrez AP. Elevated T-maze as an animal model of memory: effects of scopolamine. Behav Pharmacol 2002;13:139-48.
33. D'Hooge R, De Deyn PP. Applications of the Morris water maze in the study of learning and memory. Brain Res Rev 2001;36:60-90.
34. Falsafi SK, Deli A, Höger H, Pollak A, Lubec G. Scopolamine administration modulates muscarinic, nicotinic and NMDA receptor systems. PLoS ONE 2012 Feb 27. [Epub ahead of print] doi: 10.1371/journal.pone.0032082
35. Gacar N, Mutlu O, Utkan T, Komsuoglu Celikyurt I, Gocmez SS, Ulak G. Beneficial effects of resveratrol on scopolamine but not mecamylamine induced memory impairment in the passive avoidance and Morris water maze tests in rats. Pharmacol Biochem Behav 2011;99:316-23.
36. Misik J, Kassa J. A comparison of cholinesterase inhibitors in the treatment of quinuclidinyl benzilate-induced behavioural deficit in rats performing the multiple T-maze. J Appl Biomed 2014;12:211-7.
37. Sase S, Khan D, Sialana F, Höger H, Russo-Schlaff N, Lubec G. Modafinil improves performance in the multiple T-Maze and modifies GluR1, GluR2, D2 and NR1 receptor complex levels in the C57BL/6J mouse. Amino Acids 2012;43:2285-92.
38. Sharma S, Rakoczy S, Brown-Borg H. Assessment of spatial memory in mice. Life Sci 2010;87:521-36.
39. Dere E, Kart-Teke E, Huston JP, De Souza Silva MA. The case for episodic memory in animals. Neurosci Biobehav Rev 2006;30:1206-24.
40. Deiana S, Platt B, Riedel G. The cholinergic system and spatial learning. Behav Brain Res 2011;221:389-411.
41. Kirkby DL, Jones DN, Barnes JC, Higgins GA. Effects of anticholinesterase drugs tacrine and E2020, the 5-HT(3) antagonist ondansetron, and the H(3) antagonist thioperamide, in models of cognition and cholinergic function. Behav Pharmacol 1996;7:513-25.
42. Spowart-Manning L, van der Staay FJ. The T-maze continuous alternation task for assessing the effects of putative cognition enhancers in the mouse. Behav Brain Res 2004;151:37-46.
43. Kosasa T, Kuriya Y, Matsui K, Yamanishi Y. Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats. Eur J Pharmacol 1999;380:101-7.
44. Ogura H, Kosasa T, Kuriya Y, Yamanishi Y. Donepezil, a centrally acting acetylcholinesterase inhibitor, alleviates learning deficits in hypocholinergic models in rats. Methods Find Exp Clin Pharmacol 2000;22:89-95.
45. Racchi M, Mazzucchelli M, Porrello E, Lanni C, Govoni S. Acetylcholinesterase inhibitors: novel activities of old molecules. Pharmacol Res 2004;50:441-51.
46. Camps P, Formosa X, Galdeano C, Gómez T, Muñoz-Torrero D, Scarpellini M, Viayna E, Badia A, Clos MV, Camins A, Pallàs M, Bartolini M, Mancini F, Andrisano V, Estelrich J, Lizondo M, Bidon-Chanal A, Luque FJ. Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation. J Med Chem.2008;51(12):3588-98.
47. Dronfield S, Egan K, Marsden CA, Green AR. Comparison of donepezil-, tacrine-, rivastigmine- and metrifonate-induced central and peripheral cholinergically mediated responses in the rat. J Psychopharmacol 2000;14:275-9.
48. Hallak M, Giacobini E. Physostigmine, tacrine and metrifonate: the effect of multiple doses on acetylcholine metabolism in rat brain. Neuropharmacology 1989;28:199-206.
49. Korabecny J, Spilovska K, Benek O, Musilek K, Soukup O, Kuca K. Tacrine and its derivatives in the therapy of Alzheimers disease. Ceska Slov Farm 2012;61(5):210-21.
50. Fleck C, Appenroth D, Fang L, Schott Y, Lehmann J, Decker M. Investigation into the in vivo effects of five novel tacrine/ferulic acid and beta-carboline derivatives on scopolamine-induced cognitive impairment in rats using radial maze paradigm. Arzneimittelforschung 2010;60(6):299-306.
51. Pi R, Mao X, Chao X, Cheng Z, Liu M, Duan X, Ye M, Chen X, Mei Z, Liu P, Li W, Han Y. Tacrine-6-ferulic acid, a novel multifunctional dimer, inhibits amyloid-β-mediated Alzheimer's disease-associated pathogenesis in vitro and in vivo. PLoS ONE 2012 Feb 23 [Epub ahead of print] doi: 10.1371/journal.pone.0031921